LUCENTIS (Genentech)
(https://lucentis.com) 📸 Data Snapshot: May 31, 2026
Information Density — The Lens
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Info Density
Power-words vs. Substance ratio.
23
Impact Weight: 30 / 100
77% Reputation
The site contains significant substance, citing 12 million doses given since 2006 and specific physiological mechanisms like blocking vascular endothelial growth factor (VEGF). However, the information density is diluted by mandatory repetitive blocks of Important Safety Information which occupy over 50 percent of the text on every page. Specific nouns like conjunctival hemorrhage and intravitreal injection provide technical weight that counters generic marketing phrases. The ratio of medical fact to promotional fluff is exceptionally high due to pharmacological disclosure requirements.
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://lucentis.com) LUCENTIS® (ranibizumab) a Treatment Option for wAMD, DR & DME, mCNV, & RVO
LUCENTIS® (ranibizumab injection) [H2] For Patients and Caregivers [IMG: LUCENTIS® (ranibizumab injection) for Patients and Caregivers] Wet age-related macular degeneration (wet AMD) Diabetic retinopathy and diabetic macular edema (DR and DME) Myopic choroidal neovascularization (mCNV) Macular edema following retinal vein occlusion (RVO) LUCENTIS® (ranibizumab injection) [H2] For US Healthcare Professionals [IMG: LUCENTIS® (ranibizumab injection) for US Healthcare Professionals] Wet age-related macular degeneration (wet AMD) Diabetic retinopathy and diabetic macular edema (DR and DME) Myopic choroidal neovascularization (mCNV) Macular edema following retinal vein occlusion (RVO) [H4] Learn more about your eye condition and how LUCENTIS may be able to help. Over 12 million doses have been given since 2006. LUCENTIS® (ranibizumab), a VEGF inhibitor, treats wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). LUCENTIS is designed to block vascular endothelial (VASS‐cue‐ler end‐oh‐THEEL‐e‐ull) growth factor, or VEGF (vej‐EFF), from inside the eye. This may help reduce unhealthy swelling, leaking, and growth of blood vessels, which helps maintain vision. Lucentis is administered via intravitreal injection into the eye, typically performed monthly or as advised by your healthcare provider. Serious risks such as infections, retinal detachments, or arterial thromboembolic events (ATEs) are rare. Monitoring intraocular pressure before and after treatment is essential. Seek immediate care if any severe vision changes or signs of infection occur. Common side effects of LUCENTIS include conjunctival hemorrhage, eye pain, vitreous floaters, and intraocular pressure (IOP). Some individuals may also experience redness or discomfort after the injection. [H4] Important Safety Information Back to Top Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with: wet age-related macular degeneration (wAMD) macular edema following retinal vein occlusion (RVO) diabetic macular edema (DME) diabetic retinopathy (DR) myopic choroidal neovascularization (mCNV) What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away. Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection. Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive LUCENTIS. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by LUCENTIS. Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision. Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.
4423 chars
SUB-PAGE (https://lucentis.com/patient/safety.html) Safety
[H1] Important Safety Information Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with: wet age-related macular degeneration (wAMD) macular edema following retinal vein occlusion (RVO) diabetic macular edema (DME) diabetic retinopathy (DR) myopic choroidal neovascularization (mCNV) What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away. Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection. Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive LUCENTIS. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by LUCENTIS. Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision. Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.
2315 chars
SUB-PAGE (https://lucentis.com/patient/wamd.html) Wet AMD Treatment Option | LUCENTIS® (ranibizumab)
[H1] Learn how to take action against vision loss from wet AMD LUCENTIS is a prescription medicine for the treatment of wet age-related macular degeneration, or wet AMD. Explore this site to learn more about wet AMD, treatment, and what you may expect on your journey with LUCENTIS. Financial Support [H1] Learn how to take action against vision loss from wet AMD LUCENTIS is a prescription medicine for the treatment of wet age-related macular degeneration, or wet AMD. Explore this site to learn more about wet AMD, treatment, and what you may expect on your journey with LUCENTIS. Financial Support [IMG: About Wet Age-Related Macular Degeneration (wAMD)] [H5] What Is Wet AMD? About wAMD [IMG: Wet Age-Related Macular Degeneration (wAMD) and Vision] [H5] How Does wAMD Affect My Vision? Learn More [IMG: Image of LUCENTIS® (ranibizumab injection) prefilled syringe] [H5] About LUCENTIS for wAMD About LUCENTIS Wet age-related macular degeneration (wet AMD) is a chronic eye condition that damages the macula, leading to vision loss caused by abnormal blood vessel growth. If left untreated, wet AMD may severely affect your vision. LUCENTIS® (ranibizumab) is an FDA-approved medication that treats wet AMD, and is designed to block VEGF, which is responsible for the abnormal growth. LUCENTIS is administered directly via intravitreal injections, typically once a month or as determined by your doctor. It helps preserve vision and manage the progress of wet AMD for eligible patients. Learn more about how wet AMD impacts vision and discuss your treatment options with your healthcare provider. Serious risks such as infections, retinal detachments, or arterial thromboembolic events (ATEs) are rare. Monitoring intraocular pressure before and after treatment is essential. Seek immediate care if any severe vision changes or signs of infection occur. Common side effects of LUCENTIS include conjunctival hemorrhage, eye pain, vitreous floaters, and intraocular pressure (IOP). Some individuals may also experience redness or discomfort after the injection. Discover helpful resources and patient materials, including financial support options, to better navigate your wet AMD journey. Consult your doctor to see if LUCENTIS is the right treatment for you. [H4] Important Safety Information & Indication Back to Top Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD). What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away. Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection. Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision. Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.
4362 chars
SUB-PAGE (https://lucentis.com/patient/dr-dme.html) DR & DME Treatment Option | LUCENTIS® (ranibizumab)
[H1] Learn how to take action against vision loss from DR and DME LUCENTIS is a prescription medicine for the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME). Explore this site to learn more about DR, DME, treatment, and what you may expect on your journey with LUCENTIS. Financial Support [H1] Learn how to take action against vision loss from DR and DME LUCENTIS is a prescription medicine for the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME). Explore this site to learn more about DR, DME, treatment, and what you may expect on your journey with LUCENTIS. Financial Support [IMG: About Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)] [H5] What Are DR and DME? About DR and DME [IMG: Risk Factors of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)] [H5] What Are the Risk Factors for DR and DME? Learn More [IMG: Image of LUCENTIS® (ranibizumab injection) prefilled syringe] [H5] About LUCENTIS for DR and DME About LUCENTIS Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are serious eye conditions caused by damage to the retina from diabetes, leading to vision loss. If untreated, DR and DME can progressively impair vision and significantly impact daily life. LUCENTIS® (ranibizumab) is an FDA-approved treatment for DR and DME, designed to target VEGF to reduce swelling, prevent further damage, and help maintain vision and slow the progression of your disease. LUCENTIS is administered through intravitreal injections, typically on a monthly basis, or as decided by your doctor. Your treatment plan will depend on your condition and needs. Learn more about how DR and DME can affect vision and work with your healthcare provider to create a treatment approach to protect your eyesight. Serious risks such as infections, retinal detachments, or arterial thromboembolic events (ATEs) are rare. Monitoring intraocular pressure before and after treatment is essential. Seek immediate care if any severe vision changes or signs of infection occur. Common side effects of LUCENTIS include conjunctival hemorrhage, eye pain, vitreous floaters, and intraocular pressure (IOP). Some individuals may also experience redness or discomfort after the injection. Explore helpful resources or connect with financial support programs for more information on managing your DR or DME. Ask your doctor if LUCENTIS is right for you. [H4] Important Safety Information & Indication Back to Top Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with diabetic retinopathy (DR) and diabetic macular edema (DME). What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away. Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection. Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive LUCENTIS. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by LUCENTIS. Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision. Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.
4823 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…
Explore the other reputation pillars for LUCENTIS (Genentech)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from LUCENTIS (Genentech), captured on May 31, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to LUCENTIS (Genentech): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://lucentis.com to view the most current version of its content and see directly what this company is about and what it offers.